In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.
about
Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelAnalysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisCeftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelActivated ClpP kills persisters and eradicates a chronic biofilm infectionAssessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulEvaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic modelActivities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection modelIn vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic modelBactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.What in vitro models of infection can and cannot do.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBInfluences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a releaseLinezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection modelEvaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic ModelPenicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin SynergyAmpicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
P2860
Q28481497-A82A3A03-8647-4ED3-AB44-360A68D0B4F7Q28540482-8C09C010-C9B9-4320-81C8-0B0A555665B6Q30452801-2CC01639-D655-49C3-9AD9-3BD0C5929EF9Q33555775-7736FE53-8959-4F9A-BD0B-CB74399BEB83Q33593883-7C362681-F95D-4F8D-98F3-7B4F4A1FB043Q33653007-82E86A43-BBF9-4DE6-B00C-9419939EA96DQ33693370-6E7780EB-4F91-4A86-B7C6-8A10DCADBCC9Q33700022-AC516B08-5C07-4047-90F4-24986A9D40BEQ33758174-88BD4447-DC32-4B79-97AE-8C84631AEF5DQ33876615-0188AB58-780D-4BA8-AB5B-FF0BFA9A7846Q33883648-44B579F7-55CA-4D52-A9BB-F2C7A0C72DFAQ33976444-A6D3D7D2-7B42-4043-B45E-C24DB0FE5514Q33979347-60C2D228-37EB-4D8F-B164-EB256F358BB2Q33980074-5790AFD2-8E51-41EF-BB6F-1B916F1DA25DQ34111132-F728F397-2921-48FE-929A-146563F56043Q34230034-BEE42084-880F-45F2-B3AE-4B78FE7F4E1AQ34443398-4EFEBE49-114E-453B-9E8D-5B10AF845334Q34591451-8DC3B16B-BF0B-42D9-8BBC-4FC3D8933182Q34937048-A8775115-E741-4BEA-A874-0366B1C5487CQ35013754-CE5485A2-1329-496B-BEDA-007549C45F63Q35116133-52032AD3-01C4-4CE5-A1D1-BDA8B19B8823Q35123155-1E774FB7-3F3B-44E2-BC7F-14C3B7D172ECQ35134599-A19EB4AF-B553-4007-AD76-AE4039C444BEQ35138989-FEE32983-3FB2-4948-B996-91B10ACF7F85Q35385108-D39C1C92-6617-4B93-82BA-70190CDC0642Q35385713-2E26472A-E2FD-4CB6-B46D-C1682CD18179Q35689222-631DADD1-E7F1-40C3-858C-72FE777116CBQ35746264-8692A2D8-3163-4C7D-93C5-E0EE883E934BQ35819487-33F69924-8A79-463A-A9CF-074DA6DBA7C1Q35820123-D5A194C7-548E-4BEE-851F-A724755F7ADCQ35822889-DF4E24C6-D655-4579-AAEE-E1619F969FB9Q35859931-D8E7A8B5-9324-41B3-98B3-0A8F8C51C42BQ36439093-F873BAAB-4646-4016-BB22-99D2484AB013Q36887732-22F0EE40-57B7-48BE-8AAF-1F59C423F4B1Q37023118-FB760717-25BC-4410-A530-776DB253251DQ37203872-53C740CD-2BF8-4074-BAD3-AA6F94052554Q37250189-1DCB07F2-6E40-460D-8316-1CD252DB414FQ37287661-BF46FCC1-E7E9-4328-9F7D-C9593C102872Q37333049-ABEC6F3F-7019-415F-B47E-8405FB2FEFCCQ37538644-73D3F809-349B-4E56-8107-125EB11B75D3
P2860
In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
In-vitro model for simultaneou ...... ugs with different half-lives.
@en
In-vitro model for simultaneou ...... ugs with different half-lives.
@nl
type
label
In-vitro model for simultaneou ...... ugs with different half-lives.
@en
In-vitro model for simultaneou ...... ugs with different half-lives.
@nl
prefLabel
In-vitro model for simultaneou ...... ugs with different half-lives.
@en
In-vitro model for simultaneou ...... ugs with different half-lives.
@nl
P356
P1476
In-vitro model for simultaneou ...... ugs with different half-lives.
@en
P2093
P304
P356
10.1093/JAC/15.SUPPL_A.125
P407
P478
15 Suppl A
P577
1985-01-01T00:00:00Z